Advertisement

Is Haemophilus influenzae Type b Disease Finished?

  • Dominic Kelly
  • E. Richard Moxon
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 549)

Abstract

Haemophilus influenzae type b (Hib) has been the subject of much pioneering biomedical research. An important pathogen of childhood, it was one of the second bacteria demonstrated to be naturally transformable, the source for the identification and isolation of the first restriction endonuclease (Hindll), the target of the first glycoconjugate vaccine, and the first free living organism for which there was a complete genome sequence. In countries where Hib glyco-conjugate vaccines have been introduced into the routine infant immunization schedule, Hib has been eliminated as a major source of childhood disease. The success of this vaccine may appear to signal the end of the Hib era. Despite this success, there remain large areas of ignorance about the basic immunobiology of conjugate vaccines. Accumulating experience with Hib conjugates has emphasized that these areas of uncertainty not only have practical significance for Hib but offer important insights into vaccine biology in general. Far from being “finished,” the fact that Hib was the first organism for which conjugate vaccines were available has placed it in the forefront of research into basic vaccine immunology. Such research will continue to cast light on the fundamental mechanisms of the human immune system and will inform the search for future vaccines against other pathogens.

Keywords

Haemophilus Influenzae Conjugate Vaccine Capsular Polysaccharide Neisseria Meningitidis Routine Immunization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alexander, H., Heidelberger M., and Leidy, G. (1944). The protective or curative element in type B H. influenzae rabbit serum. Yale J. Biol. Med. 16, 425–440.PubMedGoogle Scholar
  2. Anderson, P. (1983). Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197. Infect. Immun. 39(1), 233–238.PubMedGoogle Scholar
  3. Anderson, P., Ingram, D.L., Pichichero, M.E., and Peter, G. (2000). A high degree of natural immunologic priming to the capsular polysaccharide may not prevent Haemophilus influenzae type b meningitis. Pediatr. Infect. Dis. J. 19(7), 589–591.PubMedCrossRefGoogle Scholar
  4. Avery, O. and Goebel, W.T. (1929). Chemo-immunological studies on conjugated carbohydrate-proteins: II. Immunological specificity of synthetic sugar-protein antigens. J. Exp. Med. 50, 522–550.Google Scholar
  5. Booy, R., Moxon, E.R., MacFarlane, J.A., Mayon-White, R.T., and Slack, M.P. (1992). Efficacy of Haemophilus influenzae type B conjugate vaccine in Oxford region. Lancet 340(8823), 847.PubMedCrossRefGoogle Scholar
  6. Cadoz, M. (1998). Potential and limitations of polysaccharide vaccines in infancy. Vaccine 16(14-15), 1391–1395.PubMedCrossRefGoogle Scholar
  7. Decker, M.D., Edwards, K.M., Bradley, R., and Palmer, P. (1992). Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J. Pediatr. 120(2 Pt 1), 184–189.PubMedGoogle Scholar
  8. Englund, J.A. and Glezen, W.P. (2003). Maternal immunization with Haemophilus influenzae type b vaccines in different populations. Vaccine 21(24), 3455–3459.PubMedCrossRefGoogle Scholar
  9. Eskola, J., Peltola, H., Takala, A.K., Kayhty, H., Hakulinen, M., Karanko, V. et al. (1987). Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. N. Engl. J. Med. 317(12), 717–722.PubMedCrossRefGoogle Scholar
  10. Eskola, J., Ward, J., Dagan, R., Goldblatt, D., Zepp, F., and Siegrist, C.A. (1999). Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 354(9195), 2063–2068.PubMedCrossRefGoogle Scholar
  11. Galil, K., Singleton, R., Levine, O.S., Fitzgerald, M.A., Bulkow, L., Getty, M. et al. (1999). Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. J. Infect. Dis. 179(1), 101–106.PubMedCrossRefGoogle Scholar
  12. Granoff, D.M., Holmes, S.J., Osterholm, M.T., McHugh, J.E., Lucas, A.H., Anderson, E.L. et al. (1993). Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J. Infect. Dis. 168(3), 663–671.PubMedCrossRefGoogle Scholar
  13. Health Protection Agency. Laboratory reports of Haemophilus influenzae type B infection by age group and quarter: England and Wales: 1990-2003 (30 April 2003), http://www.hpa.org.uk/infections/topics_az/haemophilus_influenzae/data_lab_age_qtr.htm.
  14. Heath, P.T. and Ramsay, M.E. (2003). Haemophilus influenzae type b vaccine—booster campaign. BMJ 326(7400), 1158–1159.PubMedCrossRefGoogle Scholar
  15. HPA (2003). Immunisation archive 2003. Laboratory reports of Haemophilus influenzae by age group and serotype England and Wales. CDR Weekly, 1.Google Scholar
  16. Kayhty, H., Eskola, J., Peltola, H., Saarinen, L., and Makela, P.H. (1992). High antibody responses to booster doses of either Haemophilus influenzae capsular polysaccharide or conjugate vaccine after primary immunization with conjugate vaccines. J. Infect. Dis. 165(Suppl 1), S165–S166.PubMedCrossRefGoogle Scholar
  17. Kayhty, H., Karanko, V., Peltola, H., and Makela, P.H. (1984). Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: No evidence of immunologic tolerance or memory. Pediatrics 74(5), 857–865.PubMedGoogle Scholar
  18. Kroll, J.S. and Moxon, E.R. (1990). Capsulation in distantly related strains of Haemophilus influenzae type b: Genetic drift and gene transfer at the capsulation locus. J. Bacteriol. 172(3), 1374–1379.PubMedGoogle Scholar
  19. Lucas, A.H. and Granoff, D.M. (2001). Imperfect memory and the development of Haemophilus influenzae type B disease. Pediatr. Infect. Dis. J. 20(3), 235–239.PubMedCrossRefGoogle Scholar
  20. Makela, P.H. and Kayhty, H. (2002). Evolution of conjugate vaccines. Expert Rev. Vaccines 1(3), 399–410.PubMedCrossRefGoogle Scholar
  21. McVernon, J., Andrews, N., Slack, M.P., and Ramsay, M.E. (2003a). Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 361(9368), 1521–1523.PubMedCrossRefGoogle Scholar
  22. McVernon, J., Johnson, P.D., Pollard, A.J., Slack, M.P., and Moxon, E.R. (2003b). Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure. Arch. Dis. Child. 88(5), 379–383.PubMedCrossRefGoogle Scholar
  23. Mulholland, K., Hilton, S., Adegbola, R., Usen, S., Oparaugo, A., Omosigho, C. et al. (1997). Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet 349(9060), 1191–1197.PubMedCrossRefGoogle Scholar
  24. Murphy, T.V., Pastor, P., Medley, F., Osterholm, M.T., and Granoff, D.M. (1993). Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. J. Pediatr. 122(4), 517–523.PubMedCrossRefGoogle Scholar
  25. Parke, J.C., Jr., Schneerson, R., Robbins, J.B., and Schlesselman, J.J. (1977). Interim report of a controlled field trial of immunization with capsular polysaccharides of Haemophilus influenzae type b and group C Neisseria meningitidis in Mecklenburg county, North Carolina (March 1974 to March 1976). J. Infect. Dis. 136(Suppl), S51–S56.PubMedCrossRefGoogle Scholar
  26. Peltola, H., Kayhty, H., Sivonen, A., and Makela, H. (1977). Haemophilus influenzae type b capsular polysaccharide vaccine in children: A double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 60(5), 730–737.PubMedGoogle Scholar
  27. Schneerson, R., Barrera, O., Sutton, A., and Robbins, J.B. (1980). Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp. Med. 152(2), 361–376.PubMedCrossRefGoogle Scholar
  28. Siber, G.R. (1994). Pneumococcal disease: Prospects for a new generation of vaccines. Science 265(5177), 1385–1387.PubMedCrossRefGoogle Scholar
  29. Siegrist, C.A. (2003). Mechanisms by which maternal antibodies influence infant vaccine responses: Review of hypotheses and definition of main determinants. Vaccine 21(24), 3406–3412.PubMedCrossRefGoogle Scholar
  30. Smith, D.H., Peter, G., Ingram, D.L., Harding, A.L., and Anderson, P. (1973). Responses of children immunized with the capsular polysaccharide of Hemophilus influenzae, type b. Pediatrics 52(5), 637–644.PubMedGoogle Scholar
  31. Swartley, J.S., Marfin, A.A., Edupuganti, S., Liu, L.J., Cieslak, P., Perkins, B. et al. (1997). Capsule switching of Neisseria meningitidis. Proc. Natl. Acad. Sci. USA 94(1), 271–276.PubMedCrossRefGoogle Scholar
  32. Takala, A.K., Eskola, J., Leinonen, M., Kayhty, H., Nissinen, A., Pekkanen, E. et al. (1991). Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J. Infect. Dis. 164(5), 982–986.PubMedCrossRefGoogle Scholar
  33. Trotter, C.L., McVernon, J., Andrews, N.J., Burrage, M., and Ramsay, M.E. (2003). Antibody to Haemophilus influenzae type b after routine and catch-up vaccination. Lancet 361(9368), 1523–1524.PubMedCrossRefGoogle Scholar
  34. Vadheim, C.M., Greenberg, D.P., Partridge, S., Jing, J., and Ward, J.I. (1993). Effectiveness and safety of an Haemophilus influenzae type b conjugate vaccine (PRP-T) in young infants. Kaiser-UCLA Vaccine Study Group. Pediatrics 92(2), 272–279.PubMedGoogle Scholar
  35. Weinberg, G.A., Einhorn, M.S., Lenoir, A.A., Granoff, P.D., and Granoff, D.M. (1987). Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide— Neisseria meningitidis outer membrane protein conjugate vaccine. J Pediatr. 111(1), 22–27.PubMedCrossRefGoogle Scholar
  36. Wenger, J.D., Booy, R., Heath, P., and Moxon, E.R. (1997) Epidemiological impact of conjugate vaccines on invasive disease caused by Haemophilus influenzae type b. In M.M. Levine, G.C. Woodrow, J.B. Kaper, and G.S. Cobon (eds.), New Generation Vaccines, 2nd edn. Marcel Dekker Inc, New York, pp. 489–502.Google Scholar

Copyright information

© Science+Business Media New York 2004

Authors and Affiliations

  • Dominic Kelly
  • E. Richard Moxon

There are no affiliations available

Personalised recommendations